<DOC>
	<DOCNO>NCT02130700</DOCNO>
	<brief_summary>The goal clinical study determine safety efficacy VT-464 , lyase-selective inhibitor CYP17 , patient castration-resistant prostate cancer ( CRPC ) previously treat Enzalutamide , Androgen Receptor Positive Triple-Negative Breast Cancer Patients , Men ER positive Breast Cancer .</brief_summary>
	<brief_title>Oral VT-464 Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide , Androgen Receptor Positive Triple-Negative Breast Cancer Patients , Men With ER Positive Breast Cancer</brief_title>
	<detailed_description>This Phase 2 open-label study VT-464 patient progressive , metastatic castration-resistant prostate cancer ( mCRPC ) previously treat enzalutamide , female patient triple negative , AR positive breast cancer men ER positive breast cancer . The study consist five cohort : patient Cohort 1 must never receive prior chemotherapy . Patients Cohort 2 must receive least one ( ) prior course chemotherapy CRPC . Women TNBC stratify two cohort AR 1 9 % ( cohort 3 ) AR &gt; 10 % ( cohort 4 ) . Cohort 5 consist men diagnose ER+ breast cancer fail least one prior endocrine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Key Eligibility Criteria : Patients must document histological cytological evidence adenocarcinoma prostate . Must progressive , metastatic castrationresistant prostate cancer ( mCRPC ) . There must radiographic evidence disease primary treatment surgery radiotherapy continue progress radiographically biochemically ( rise PSA level successive measurement ) despite adequate androgendeprivation therapy , define undergone bilateral surgical castration continue treatment GnRH agonists antagonist . All patient trial must treat enzalutamide . Patients Cohort 1 allow receive prior chemotherapy ; patient Cohort 2 must receive one ( ) prior course chemotherapy mCRPC . Progression must evidence document follow parameter : PSA progression define minimum two rise PSA level interval â‰¥ 1 week determination Appearance one new lesion bone scan Progressive measurable disease RECIST 1.1</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mCRPC</keyword>
	<keyword>metastatic</keyword>
	<keyword>castration-resistant prostate cancer</keyword>
</DOC>